Eswatini vs Mexico: Average cost of drugs for extensively drug-resistant tuberculosis
Eswatini
2,726 constant 2022 US$
in 2024
Mexico
3,500 constant 2022 US$
in 2024
Eswatini rank
22nd
Mexico rank
19th
Average cost of drugs for extensively drug-resistant tuberculosis over time
- Eswatini
- Mexico
How they compare
Mexico currently reports 3,500 constant 2022 US$ against 2,726 constant 2022 US$ in Eswatini, a difference of 774 constant 2022 US$.
That makes Mexico's figure about 1.3 times Eswatini's.
The two have swapped places 1 time across 8 shared years of data; in 2017 it was Eswatini ahead.
Eswatini ranks 22nd and Mexico ranks 19th of 56 countries.
Eswatini has averaged higher in every one of the 2 decades both report.
Head to head by decade
| Decade | Eswatini | Mexico | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 23,224 constant 2022 US$ | 5,870 constant 2022 US$ | 17,354 constant 2022 US$ | Eswatini |
| 2020s | 9,624 constant 2022 US$ | 4,063 constant 2022 US$ | 5,561 constant 2022 US$ | Eswatini |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher average cost of drugs for extensively drug-resistant tuberculosis, Eswatini or Mexico?
- Mexico, at 3,500 constant 2022 US$ against 2,726 constant 2022 US$ in Eswatini as of 2024.
- What is the difference in average cost of drugs for extensively drug-resistant tuberculosis between Eswatini and Mexico?
- 774 constant 2022 US$, with Mexico ahead.
- How many years of comparable data are there for Eswatini and Mexico?
- 8 years are reported by both, from 2017 to 2024.
- How do Eswatini and Mexico rank globally for average cost of drugs for extensively drug-resistant tuberculosis?
- Eswatini ranks 22nd and Mexico ranks 19th of 56 countries.
- Where does this data come from?
- WHO (2025) – with minor processing by Our World in Data, published as Average cost of drugs for extensively drug-resistant tuberculosis. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Average cost of drugs spent per patient starting extensively drug-resistant tuberculosis treatment, excluding buffer stock.